

ANNUAL RESULTS AS OF JUNE 30TH, 2012

Evry, October 23rd, 2012 - Global Bioenergies, the industrial biology company developing processes for the bio-production of light olefins, publishes audited¹ annual results for the financial year ending June 30th, 2012. Results were approved by the Board of Directors on October 23rd, 2012.

- **Annual results, June 30th 2012**

In €K	from 01/07/11 until 30/06/12	from 01/07/10 until 30/06/11
Collaborations and Licenses	251	225
Subsidies	33	180
Total revenues	284	405
Operating expenses	4 233	2 384
of which laboratory expenses	1 061	568
of which wages	1 550	1 033
Operating profit/loss	-3 950	-1 979
Net profit/loss	-3 505	-1 582
	As of June 30th 2012	As of June 30th 2011
Shareholder's Equity	3 952	6 054
Cash and marketable securities	4 093	5 687
Total assets and liabilities	5 799	6 837

- **Financial results and financial situation**

Revenues excluding subsidies comprise a €150K collaboration fee and a first payment of €100K resulting from a license included in a strategic partnership. These revenues of €251K are to be compared to the €225K obtained during the 2010-11 fiscal year and represent an 11% growth.

Operating expenses reached €4.2m, representing a 78% increase from the previous fiscal year due to the expansion of the R&D teams and the strengthening of the technology platforms.

R&D tax credits ("Crédit d'Impôt Recherche", or "CIR"), amount to €0.4m and correspond to the calendar year 2011.

As a consequence of an increase in R&D expenses, a €3.5m net loss was observed for the fiscal year ending June 30th, 2012 compared to €1.6m for the previous fiscal year.

¹ Auditor's report not yet issued.

Over this last fiscal year, Global Bioenergies has continued to strengthen its shareholder's equity now amounting to €4m as of June 30th, 2012. The Company has carried out two capital increases during that financial year including one public offering which ended July 4th, 2012. As of June 30th, 2012, the Company has not contracted any debt financing. Net cash position reached €3.4m as of June 30th, 2012 and €4.5m as of September 30th, 2012²; taking into account refundable advances obtained from OSEO (€0.6m), gross cash position reached €5.1m as of September 30th, 2012.

- **Key facts and recent events**

Nomination of two Vice-Presidents

On May 9th, 2012, GLOBAL BIOENERGIES has named Mr. Charles NAKAMURA and Mr. Richard BOCKRATH as Vice-Presidents for metabolic engineering and for chemical engineering respectively. The experience and skills of these two former technological leaders from DuPont will be critical to the industrialization of the isobutene process.

Opening of a US branch

In June 2012, GLOBAL BIOENERGIES opened a branch in Ames, Iowa to deploy US activities.

Capital increase of 3 million euros by public offering

GLOBAL BIOENERGIES called on the markets through a public offering that ended July 4th, 2012. The operation allowed the Company to raise 3 million euros. It was carried out without discount at a €19.80 share price.

Receiving of the EuropaBio prize

On September 19th, 2012, GLOBAL BIOENERGIES was awarded « the most innovative European biotech SME » by EuropaBio, an organization representing more than 1,800 biotech companies in Europe.

Opening the way to propylene

Global Bioenergies has demonstrated a novel metabolic pathway enabling the direct conversion of renewable resources to propylene, one of the main building blocks of the petrochemical industry. Propylene represents an existing market of \$93 billion³.

Liliane Bronstein, Chief Financial Officer of GLOBAL BIOENERGIES, comments: "Capital raised since the initial public offering of June 2011 has allowed us to strengthen our teams, setting up a robotic screening platform and the installment of the laboratory pilot."

Marc Delcourt, CEO of GLOBAL BIOENERGIES, concludes: "Building a portfolio of bioprocesses in the targeted field of light olefins gives GLOBAL BIOENERGIES a clear and distinct identity. We expect that our progresses in developing these processes will result in strong revenues."

² Non audited information dating September 30th, 2012

³ Nexant and Platts

About Global Bioenergies

Global Bioenergies is one of few companies worldwide, and the only one in Europe, that is developing a process to convert renewable resources into hydrocarbons through fermentation. The Company initially focused its efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers. Global Bioenergies continues to improve the yield of its process and prepares the phase dedicated to pilot testing. In parallel, the Company succeeded in replicating this initial success to propylene and targets other members of the gaseous olefins family, key molecules at the heart of the petrochemical industry. Global Bioenergies is listed on NYSE Alternext Paris (FR0011052257 - ALGBE) and is part of the NYSE Alternext Oseo Innovation index.

**Should you like to be kept informed, subscribe to our news feed on
www.global-bioenergies.com**

Contacts

GLOBAL BIOENERGIES

Marc DELCOURT – CEO

Liliane BRONSTEIN – CFO

E-mail : invest@global-bioenergies.com

Tel : + 33 (0) 1 64 98 20 50

ALGBE
LISTED
NYSE
ALTERNEXT